6-aminocaproic acid 1000 MG Oral Tablet — RxCUI 476271
RxNorm drug concept · Semantic clinical drug
RxCUI 476271
Semantic clinical drug · SCD
● Current RxNorm concept 12 FDA products
14 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI476271
Official name6-aminocaproic acid 1000 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asaminocaproic acid 1000 MG Oral Tablet
FDA products mapped12
Package NDCs mapped14
Reported Medicaid activity (SDUD)1,136 prescriptions · 10 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Aminocaproic Acid: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Aminocaproic acid is used to help stop bleeding that happens when your body's own clot-dissolving system goes into overdrive. Normally that system is a good thing — it prevents clo...
- What exactly is aminocaproic acid being used for in my case?
- It depends on your situation. If you're in a hospital setting or it's an emergency, you'll likely receive it through an IV drip — slowly, over time. If you're able to take medicine...
- How will I be given this medication — will I get a pill or an IV?
🕸️ Concept Web — How 6-aminocaproic acid 1000 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
6-aminocaproic acid 1000 MG Oral Tablet
RxCUI 476271 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
6-aminocaproic acid
99IN
-
6-aminocaproic acid
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Amicar
204292BN
-
Amicar
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
6-aminocaproic acid Oral Tablet
378772SCDF -
6-aminocaproic acid Oral Product
1152516SCDG -
6-aminocaproic acid Pill
1152517SCDG -
6-aminocaproic acid Oral Tablet [Amicar]
369436SBDF -
Amicar Oral Product
1171387SBDG -
Amicar Pill
1171388SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
6-aminocaproic acid Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
6-aminocaproic acid 1000 MG
476272SCDC -
6-aminocaproic acid 1000 MG Oral Tablet [Amicar]
540540SBD -
6-aminocaproic acid 1000 MG [Amicar]
540539SBDC
-
6-aminocaproic acid 1000 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
6-aminocaproic acid 1000 MG
SCDC · 476272 -
6-aminocaproic acid Oral Tablet
SCDF · 378772 -
6-aminocaproic acid Oral Product
SCDG · 1152516 -
6-aminocaproic acid Pill
SCDG · 1152517
Brand-Name Concepts
-
6-aminocaproic acid 1000 MG Oral Tablet [Amicar]
SBD · 540540 -
6-aminocaproic acid 1000 MG [Amicar]
SBDC · 540539 -
6-aminocaproic acid Oral Tablet [Amicar]
SBDF · 369436 -
Amicar Oral Product
SBDG · 1171387 -
Amicar Pill
SBDG · 1171388 -
Amicar
BN · 204292
📦 FDA Products & Package NDCs
12 products · 14 package NDCs
14 package NDCs map to RxCUI 476271 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00054-1100-58 | 236.5 mL in 1 BOTTLE, PLASTIC (0054-1100-58) | Aminocaproic Acid | Hikma Pharmaceuticals USA Inc. | 2024-11-12 |
| 00054-1110-13 | 30 TABLET in 1 BOTTLE (0054-1110-13) | Aminocaproic Acid | Hikma Pharmaceuticals USA Inc. | 2024-11-12 |
| 24658-0798-30 | 30 TABLET in 1 BOTTLE (24658-798-30) | AMINOCAPROIC ACID | PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS | 2023-01-24 |
| 24658-0799-30 | 30 TABLET in 1 BOTTLE (24658-799-30) | AMINOCAPROIC ACID | PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS | 2023-01-24 |
| 69680-0115-00 | 100 TABLET in 1 BOTTLE (69680-115-00) | Aminocaproic Acid | Vitruvias Therapeutics | 2018-12-03 |
| 69680-0115-30 | 30 TABLET in 1 BOTTLE (69680-115-30) | Aminocaproic Acid | Vitruvias Therapeutics | 2018-12-03 |
| 69680-0116-00 | 100 TABLET in 1 BOTTLE (69680-116-00) | Aminocaproic Acid | Vitruvias Therapeutics | 2018-12-03 |
| 69680-0116-30 | 30 TABLET in 1 BOTTLE (69680-116-30) | Aminocaproic Acid | Vitruvias Therapeutics | 2018-12-03 |
| 70377-0102-11 | 30 TABLET in 1 BOTTLE (70377-102-11) | AMINOCAPROIC ACID | Biocon Pharma Inc. | 2021-03-15 |
| 70377-0103-11 | 30 TABLET in 1 BOTTLE (70377-103-11) | AMINOCAPROIC ACID | Biocon Pharma Inc. | 2021-03-15 |
| 72205-0049-30 | 30 TABLET in 1 BOTTLE (72205-049-30) | Aminocaproic acid | Novadoz Pharmaceuticals LLC | 2020-12-10 |
| 72205-0286-30 | 30 TABLET in 1 BOTTLE (72205-286-30) | Aminocaproic acid | Novadoz Pharmaceuticals LLC | 2023-09-21 |
| 80005-0128-08 | 30 TABLET in 1 BOTTLE (80005-128-08) | AMINOCAPROIC ACID | Carnegie Pharmaceuticals, LLC | 2021-03-15 |
| 80005-0129-08 | 30 TABLET in 1 BOTTLE (80005-129-08) | AMINOCAPROIC ACID | Carnegie Pharmaceuticals, LLC | 2021-03-15 |
Observed labelers:
Vitruvias Therapeutics (4) ·
Biocon Pharma Inc. (2) ·
Carnegie Pharmaceuticals, LLC (2) ·
Hikma Pharmaceuticals USA Inc. (2) ·
Novadoz Pharmaceuticals LLC (2) ·
PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.